DK2956471T3 - Il-1beta-hæmmersammensætning og anvendelse deraf - Google Patents

Il-1beta-hæmmersammensætning og anvendelse deraf Download PDF

Info

Publication number: DK2956471T3
Authority: DK; Denmark
Prior art keywords: inhibitor composition; 1beta; 1beta inhibitor; composition; inhibitor
Prior art date: 2013-02-15

Application number

DK13875211.8T

Other languages

English (en)

Inventor

Yan Lavrovsky

Ting Xu

Alexey Repik

Tao Xu

Vasily Ignatiev

Mikhail Samsonov

Original Assignee

R Pharm Int Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-15

Filing date

2013-02-15

Publication date

2024-05-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51354448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2956471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-15 Application filed by R Pharm Int Llc filed Critical R Pharm Int Llc

2024-05-21 Application granted granted Critical

2024-05-21 Publication of DK2956471T3 publication Critical patent/DK2956471T3/da

Links

239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

DK13875211.8T 2013-02-15 2013-02-15 Il-1beta-hæmmersammensætning og anvendelse deraf DK2956471T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2013/026349 WO2014126582A1 (en)	2013-02-15	2013-02-15	IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Publications (1)

Publication Number	Publication Date
DK2956471T3 true DK2956471T3 (da)	2024-05-21

Family

ID=51354448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13875211.8T DK2956471T3 (da)	2013-02-15	2013-02-15	Il-1beta-hæmmersammensætning og anvendelse deraf

Country Status (24)

Country	Link
EP (2)	EP4050019A1 (da)
JP (1)	JP6225197B2 (da)
KR (1)	KR101989551B1 (da)
CN (1)	CN105431448B (da)
AU (1)	AU2013378122B2 (da)
BR (1)	BR112015019729B1 (da)
DK (1)	DK2956471T3 (da)
EA (1)	EA033269B1 (da)
ES (1)	ES2990881T3 (da)
FI (1)	FI2956471T3 (da)
HR (1)	HRP20240641T1 (da)
HU (1)	HUE067221T2 (da)
IL (1)	IL240553B (da)
LT (1)	LT2956471T (da)
MX (1)	MX390047B (da)
NZ (1)	NZ710900A (da)
PH (1)	PH12015501796A1 (da)
PL (1)	PL2956471T3 (da)
PT (1)	PT2956471T (da)
RS (1)	RS65559B1 (da)
SG (1)	SG11201506389YA (da)
SI (1)	SI2956471T1 (da)
SM (1)	SMT202400191T1 (da)
WO (1)	WO2014126582A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6225197B2 (ja)	2013-02-15	2017-11-01	アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ	ＩＬ−１β阻害剤組成物およびその使用
US12180264B2 (en)	2014-03-24	2024-12-31	R-Pharm Overseas, Inc.	IL1-R1 derived inhibitor of IL-1β and use thereof
CN104628870A (zh) *	2015-02-04	2015-05-20	中国药科大学	一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN104725514A (zh) *	2015-02-06	2015-06-24	中国药科大学	新型il23拮抗剂
WO2018228442A1 (en)	2017-06-14	2018-12-20	Dingfu Biotarget Co., Ltd.	Proteinaceous heterodimer and use thereof
SI3687562T1 (sl)	2017-09-26	2025-06-30	Regeneron Pharmaceuticals, Inc.	Zdravljenje ponavljajočega se idiopatskega perikarditisa z dajanjem fuzijskega proteina antagonista receptorja za interlevkin-1
BR112022022089A2 (pt) *	2020-05-22	2022-12-13	R Pharm Overseas Inc	Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss
KR20220014531A (ko) *	2020-07-29	2022-02-07	(주)메디톡스	헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법
CN116144668A (zh) *	2023-02-13	2023-05-23	杭州吉倍思生物制药有限公司	人il-1r1基因、蛋白、同源二聚体蛋白质与用途
CN116286844A (zh) *	2023-02-13	2023-06-23	浙江大学	人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途
WO2026128826A1 (en)	2024-12-12	2026-06-18	Regeneron Pharmaceuticals, Inc.	Treatment of cardiac sarcoidosis with interleukin-1 receptor-fc fusion protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
US6472179B2 (en)	1998-09-25	2002-10-29	Regeneron Pharmaceuticals, Inc.	Receptor based antagonists and methods of making and using
ES2335232T3 (es) *	2005-06-21	2010-03-23	Xoma Technology Ltd.	Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
US7666622B2 (en) *	2005-10-19	2010-02-23	Regeneron Pharmaceuticals, Inc.	Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP3663318A1 (en) *	2008-01-07	2020-06-10	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2686348B1 (en)	2011-03-17	2015-12-30	Ramot at Tel-Aviv University Ltd.	Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2014035361A1 (en) *	2012-08-26	2014-03-06	R-PHARM, CJSC (Closed Joint Stock Company)	IL-1β INHIBITOR COMPOSITION AND USE THEREOF
JP6225197B2 (ja)	2013-02-15	2017-11-01	アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ	ＩＬ−１β阻害剤組成物およびその使用

2013
- 2013-02-15 JP JP2015557984A patent/JP6225197B2/ja active Active
- 2013-02-15 EA EA201500842A patent/EA033269B1/ru unknown
- 2013-02-15 EP EP21208571.6A patent/EP4050019A1/en active Pending
- 2013-02-15 PL PL13875211.8T patent/PL2956471T3/pl unknown
- 2013-02-15 SG SG11201506389YA patent/SG11201506389YA/en unknown
- 2013-02-15 RS RS20240597A patent/RS65559B1/sr unknown
- 2013-02-15 SI SI201332081T patent/SI2956471T1/sl unknown
- 2013-02-15 ES ES13875211T patent/ES2990881T3/es active Active
- 2013-02-15 KR KR1020157025393A patent/KR101989551B1/ko active Active
- 2013-02-15 PT PT138752118T patent/PT2956471T/pt unknown
- 2013-02-15 WO PCT/US2013/026349 patent/WO2014126582A1/en not_active Ceased
- 2013-02-15 HU HUE13875211A patent/HUE067221T2/hu unknown
- 2013-02-15 SM SM20240191T patent/SMT202400191T1/it unknown
- 2013-02-15 HR HRP20240641TT patent/HRP20240641T1/hr unknown
- 2013-02-15 LT LTEPPCT/US2013/026349T patent/LT2956471T/lt unknown
- 2013-02-15 MX MX2015010438A patent/MX390047B/es unknown
- 2013-02-15 AU AU2013378122A patent/AU2013378122B2/en active Active
- 2013-02-15 BR BR112015019729-9A patent/BR112015019729B1/pt active IP Right Grant
- 2013-02-15 CN CN201380075648.9A patent/CN105431448B/zh active Active
- 2013-02-15 NZ NZ71090013A patent/NZ710900A/en unknown
- 2013-02-15 FI FIEP13875211.8T patent/FI2956471T3/fi active
- 2013-02-15 DK DK13875211.8T patent/DK2956471T3/da active
- 2013-02-15 EP EP13875211.8A patent/EP2956471B1/en active Active
2015
- 2015-08-12 IL IL240553A patent/IL240553B/en active IP Right Grant
- 2015-08-14 PH PH12015501796A patent/PH12015501796A1/en unknown

Also Published As

Publication number	Publication date
KR20160048028A (ko)	2016-05-03
BR112015019729B1 (pt)	2023-01-24
EA033269B1 (ru)	2019-09-30
SMT202400191T1 (it)	2024-07-09
EP2956471A1 (en)	2015-12-23
SI2956471T1 (sl)	2024-06-28
HUE067221T2 (hu)	2024-10-28
HK1219281A1 (en)	2017-03-31
JP6225197B2 (ja)	2017-11-01
MX2015010438A (es)	2016-05-05
IL240553A0 (en)	2015-10-29
AU2013378122B2 (en)	2019-05-02
PT2956471T (pt)	2024-05-27
LT2956471T (lt)	2024-06-10
CN105431448B (zh)	2019-08-27
MX390047B (es)	2025-03-20
PH12015501796B1 (en)	2015-11-09
AU2013378122A1 (en)	2015-08-27
EP4050019A1 (en)	2022-08-31
IL240553B (en)	2021-02-28
CN105431448A (zh)	2016-03-23
BR112015019729A2 (pt)	2017-07-18
PH12015501796A1 (en)	2015-11-09
KR101989551B1 (ko)	2019-09-30
WO2014126582A1 (en)	2014-08-21
PL2956471T3 (pl)	2024-06-24
EP2956471B1 (en)	2024-04-10
RS65559B1 (sr)	2024-06-28
EP2956471A4 (en)	2019-11-13
JP2016513106A (ja)	2016-05-12
FI2956471T3 (fi)	2024-05-13
HRP20240641T1 (hr)	2025-06-20
ES2990881T3 (es)	2024-12-02
EA201500842A1 (ru)	2016-02-29
SG11201506389YA (en)	2015-09-29
NZ710900A (en)	2019-09-27

Publication	Publication Date	Title
IL267681B (en)	2022-11-01	Selective grp94 inhibitors and uses thereof
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3058936T3 (da)	2019-05-13	Peptidsammensætning og anvendelser deraf
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3381917T3 (da)	2021-10-18	Imidazopyridinforbindelser og anvendelser deraf
DK3018183T3 (da)	2022-12-05	Halogenolefinbaseret sammensætning og anvendelse deraf
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3052485T3 (da)	2021-10-11	Heterocykliske forbindelser og anvendelser deraf
DK2970132T3 (da)	2020-12-21	Argininmethyltransferaseinhibitorer og anvendelser deraf
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2968173T3 (da)	2020-12-21	Heterocykliske forbindelser og anvendelser deraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3011041T3 (da)	2020-05-18	Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter
DK2964767T3 (da)	2020-03-23	Toksingener og fremgangsmåder til anvendelse deraf
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
HRP20182134T1 (hr)	2019-02-08	Triazinski spoj i njegova upotreba u medicinske svrhe
DK3030519T3 (da)	2022-01-31	Tricykliske benzoxaborol-forbindelser og anvendelser deraf
HRP20181291T1 (hr)	2018-10-19	Heterobicikloarilni inhibitori rorc2 i njihova upotreba
DK3060200T3 (da)	2021-07-12	Tyrosinderivater og sammensætninger dermed
DK3326642T3 (da)	2021-02-22	Langtidsvirkende koagulationsfaktorer og brugen deraf
PT2956471T (pt)	2024-05-27	Composição inibidora de il-1beta e sua utilização
DK2958926T3 (da)	2023-05-22	Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf